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Abstract Polymeric nanoparticles have been extensively studied as particulate carriers in the pharmaceutical
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E-mail address: nand medical fields, because they show promise as drug delivery systems as a result of their
controlled- and sustained-release properties, subcellular size, and biocompatibility with tissue and
cells. Several methods to prepare nanoparticles have been developed during the last two decades,
classified according to whether the particle formation involves a polymerization reaction or arises
from a macromolecule or preformed polymer. In this review the most important preparation methods
are described, especially those that make use of natural polymers. Advantages and disadvantages will
be presented so as to facilitate selection of an appropriate nanoencapsulation method according to a
particular application.D 2006 Elsevier Inc. All rights reserved.Key words: Drug delivery; Nanoparticles; Preparation methodsNanoencapsulation of drugs involves forming drug-
loaded particles with diameters ranging from 1 to 1000 nm.
Nanoparticles are defined as solid, submicron-sized drug
carriers that may or may not be biodegradable [1,2]. The term
nanoparticle is a collective name for both nanospheres and
nanocapsules. Nanospheres have a matrix type of structure.
Drugs may be absorbed at the sphere surface or encapsulated
within the particle. Nanocapsules are vesicular systems in
which the drug is confined to a cavity consisting of an inner
liquid core surrounded by a polymeric membrane [1]. In this
case the active substances are usually dissolved in the inner
core but may also be adsorbed to the capsule surface [3].
Nanoparticles are receiving considerable attention for the
delivery of therapeutic drugs. The literature emphasizes the
advantages of nanoparticles over microparticles [4] and
liposomes [5,6]. The submicron size of nanoparticles offersnt matter D 2006 Elsevier Inc. All rights reserved.
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ity, Kingston, Ontario, Canada K7L3N6.
eufeld@chee.queensu.ca (R.J. Neufeld).a number of distinct advantages over microparticles, includ-
ing relatively higher intracellular uptake compared with
microparticles. In terms of intestinal uptake, apart from their
particle size, nanoparticle nature and charge properties seem
to influence the uptake by intestinal epithelia. Uptake of
nanoparticles prepared from hydrophobic polymers seems to
be higher than that of particles withmore hydrophilic surfaces
[7], thus more hydrophilic particles may be rapidly eliminat-
ed. Generally, nanoparticles based in hydrophobic polymers
such as poly(styrene), uncharged and positively charged,
provide an affinity to follicle-associated epithelia as well as
to absorptive enterocytes, whereas negatively charged poly
(styrene) nanoparticles show only low affinity to any type of
intestinal tissues. In contrast, nanoparticles based on hydro-
philic polymers, negatively charged, show a strong increase
in bioadhesive properties and are absorbed by both M cells
and absorptive enterocytes. A combination of both nano-
particle surface charges and increased hydrophilicity of the
matrix material seem to affect the gastrointestinal uptake in a
positive sense.Biology, and Medicine 2 (2006) 8–21
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consideration in targeting drug delivery. Indeed, once in
the bloodstream, generally conventional nanoparticles (no
surface modification) and negatively charged particles can
be rapidly opsonized and massively cleared by the fixed
macrophages. It is well known that the reticuloendothelial
system, mainly the liver and spleen, is a major obstacle to
active targeting because of its ability to recognize these
systems, remove them from systemic circulation, and,
consequently, avoid the effective delivery of the nano-
spheres to organs other than those of the reticuloendothelial
system [8]. Surface modification of these nanoparticulate
systems with hydrophilic polymers is the most common way
to control the opsonization process and to improve the
surface properties of the system, or coating modification
with polymers [6] such as the attachment of poly(ethylene
glycol) (PEG) chains to biodegradable polymer such as
poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid)
(PLGA). Thus the hydrophilic PEG chains allow the control
of protein and peptide absorption and, in addition will allow
regulation of cell behavior at the polymer surface.
Thus the polymeric composition (hydrophobicity, surface
charge, and biodegradation profile) of the nanoparticles, any
adjuvant substances, and the associated drug (molecular
weight, charge, localization in the nanospheres by adsorp-
tion or incorporation) have a great influence on the drug
absorption, biodistribution pattern, and elimination. There
are now numerous preparation methods available for
producing nanoparticles.
Depending on the physicochemical characteristics of
a drug, it is now possible to choose the best method of
preparation and the best polymer to achieve an efficient
entrapment of the drug. Moreover, organic solvents assessed
in this review are classified according to International
Conference on Harmonization (ICH) classification according
to their possible risk to human health and placed into one of
three classes as follows: class 1 (solvents to be avoided), class
2 (solvents to be limited), and class 3 (solvents with low toxic
potential). This classification will be crucial to evaluate the
following methods and finally, to apply a specific technique
to a particular pharmaceutical application.Methods
Many methods have been developed for preparing nano-
particles; these methods can be classified into two main
categories according to whether the formulation requires a
polymerization reaction or is achieved directly from a
macromolecule or preformed polymer [1]. The polymeriza-
tion methods can be further classified into emulsion and
interfacial polymerization, and there are two types of
emulsion polymerization—organic and aqueous—depend-
ing on the continuous phase. Additionally, the interfacial
condensation method will be further discussed later in this
review. Nanoparticles can be also prepared directly from
preformed synthetic or natural polymers and by desolvationof macromolecules. Recently these polymeric systems have
been prepared by nebulization techniques. This review
covers all these methods including their detailed procedures
and technological advantages, as well as providing several
examples of encapsulants that are entrapped into or adsorbed
to these particles. The most important methods of nano-
particle preparation, as well as the encapsulants and the
resulting approximate particle sizes, are shown in Table 1.
Nanoparticles obtained by polymerization of a monomer
Emulsion polymerization
Emulsion polymerization is one of the fastest methods
for nanoparticle preparation and is readily scalable [9]. The
method is classified into two categories, based on the use of
an organic or aqueous continuous phase.
The continuous organic phase methodology involves the
dispersion of monomer into an emulsion or inverse micro-
emulsion, or into a material in which the monomer is not
soluble (nonsolvent). Polyacrylamide nanospheres were
produced by this method [10,11]. As one of the first
methods for production of nanoparticles, surfactants or
protective soluble polymers were used to prevent aggrega-
tion in the early stages of polymerization [12]. This
procedure has become less important, because it requires
toxic organic solvents, surfactants, monomers and initiator,
which are subsequently eliminated from the formed
particles. As a result of the nonbiodegradable nature of this
polymer as well as the difficult procedure, alternative
approaches are of greater interest. Later, poly(methylmetha-
crylate) (PMMA), poly(ethylcyanoacrylate) (PECA), and
poly(butylcyanoacrylate) [13] nanoparticles were produced
by dispersion via surfactants into solvents such as cyclo-
hexane (ICH, class 2), n-pentane (ICH, class 3), and toluene
(ICH, class 2) as the organic phase. Examples of drugs
encapsulated with this system are triamcinolone [14],
fluorescein [13], pilocarpine [15], and timolol [15].
In the aqueous continuous phase the monomer is
dissolved in a continuous phase that is usually an aqueous
solution, and the surfactants or emulsifiers are not needed.
The polymerization process can be initiated by different
mechanisms. Initiation occurs when a monomer molecule
dissolved in the continuous phase collides with an initiator
molecule that might be an ion or a free radical. Alterna-
tively, the monomer molecule can be transformed into an
initiating radical by high-energy radiation, including
g-radiation, or ultraviolet or strong visible light. Chain
growth starts when initiated monomer ions or monomer
radicals collide with other monomer molecules according to
an anionic polymerization mechanism [16]. Phase separa-
tion and formation of solid particles can take place before or
after termination of the polymerization reaction [17].
PMMA nanoparticles are suitable adjuvants for vaccines
and are produced by a radical emulsion polymerization
mechanism [18]—generally without emulsifiers [19]. The
single monomer methylmethacrylate (MMA) was used to
Table 1
Examples of preparative methods, polymers, and encapsulants
Polymer Encapsulant Size (nm) Reference
Nanoparticles obtained by polymerization of a monomer
Emulsion polymerization
Continuous aqueous phase
Poly(methylmethacrylate)
Influenza antigen 130 [121]
Poly(methylmethacrylate) copolymers Doxorubicin 300 [20]
Poly(methylcyanoacrylate) Vinblastine 200–300 [122]
Poly(ethylcyanoacrylate) Insulin b500 [123]
Poly(butylcyanoacrylate) Progesterone 250 [27]
Poly(isobutylcyanoacrylate) Ampicillin
Antibodies
hGRF
40–80
120
140–170
[24]
[31]
[30]
Poly(hexylcyanoacrylate) Vincamine 200 [124]
Poly(isohexylcyanoacrylate) Ampicillin
Doxorubicin
30–80
300
[24]
[25]
Poly(dialkylmethylidene malonate) Primaquine b1000 [33]
Continuous organic phase
Polyacrylamide Enzymes b1000 [10]
Poly(methylcyanoacrylate) Triamcinolone
Fluorescein
Pilocarpine
500
800–1000
300–600
[14]
[13]
[15]
Other polymers: Poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(styrene), poly(vinylpyridine) and poly(acroleine)
Interfacial polymerization
Poly(ethylcyanoacrylate) Insulin ~151 [36]
Poly(isobutylcyanoacrylate) Indomethacin
Darodipine
Insulin
Calcitonin
Octreotide
220240
150
150–300
b1000
260
[43,44]
[42]
[40]
[11]
[41]
Poly(isohexylcyanoacrylate) Phthalocyanines 180 [39]
Other polymers: Polyamides, poly(phenylesters) and polyurethanes
Interfacial polycondensation
Polyurethane and poly(etherurethane) a-Tocopherol b 500 [49]
Nanoparticles obtained directly from a macromolecule
or a preformed polymer
Nanoparticles prepared with synthetic/semi-synthetic
preformed polymer
Solvent evaporation
Poly(lactic acid) Testosterone
Albumin
Tetanus toxoid
Loperamide
b1000
100 or 120
150
~300
[52]
[61]
[62]
[53,63]
Poly(lactic acid)–poly(glycolic acid) copolymer DNA
Cyclosporin A
~100
~300
[67]
[66]
Other polymers: Poly(E-caprolactone) and poly(h-Hydroxybutyrate) [60]
Solvent displacement
Poly(lactic acid)–poly(glycolic acid) copolymer Indomethacin
Doxorubicin
Cyclosporin A
Valproic acid
Ketoprofen
Vancomycin
Insulin
~168
274
~170
~166
~167
~187
~105–170
[69]
[25]
[69]
[69]
[69]
[69]
[69]
Poly(lactic acid) Doxorubicin
Taxol
Dexamethasone
Vitamin K
270
~260
~300
~270
[25]
[68]
[68]
[68]
Poly(E-caprolactone) Cyclosporin A ~100–200 [75]
Other polymers: h-cyclodextrin inclusion complexes [78], PVM/MA [125], and –poly(alkylmethacrylate)
Interfacial deposition
Poly(lactic acid) Indomethacin 230 [44,68,79]
Salting-out
Poly(lactic acid) Savoxepin b1000 [126]
Other polymers: Poly(alkylmethacrylate) and ethylcellulose
Emulsion/solvent diffusion
Poly(lactic acid)–poly(glycolic acid) copolymer p-THPP
Doxorubicin
117–118
b1000
[127]
[82]
Poly(lactic acid) p-THPP
DNA
125
b300
[127]
[83]
(continued on next page)
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Table 1 (continued)
Other polymer: Poly(E-caprolactone)
Nanoparticles produced from natural macromolecules
Serum albumin Doxorubicin 200–1500 [89]
Gelatin Mitomycin C 280 [92]
Polysaccharides Oligonucleotides b1000 [128,129]
Doxorubicin b1000 [25]
Insulin b1000 [96]
Tetanus and diphtheria toxoid b1000 [6]
Calcitonin b1000 [102]
Desolvation of macromolecules4
Gelatin DNA b1000 [116]
Cytostatics [117]
Other polymers: casein, albumin and ethylcellulose
Nebulization techniques
Poly(lactic acid) Insulin 400–600 [130]
hGRF, human growth hormone–releasing factor; p-THPP, mesotetra(hydroxyphenyl)porphyrin.
4 Induced by heat, pH changes, salts, organic solvents, complexing with macromolecules, sonication, or chemical cross-linking.
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merization of MMA, hydroxypropylmethacrylate, metha-
crylic acid, and ethylene glycol dimethacrylate was described
to increase the hydrophilicity of the particles with the
intention of modifying the distribution of the particles within
the body [3]. Various drugs or tracers were encapsulated into
nanospheres with high entrapment efficiencies (eg, doxoru-
bicin) [20]. The preparation of PMMA nanospheres is simple
and drugs can be successfully entrapped, but two drawbacks
have to be kept in mind. First, polymerization requires a
chemical or physical initiation, and second, PMMA nano-
spheres are not biodegradable [21].
As a result, poly(alkylcyanoacrylate) (PACA) nano-
particles seem to be a good alternative, in that PACA is
readily biodegradable [22]. Polymerization occurs at room
temperature and requires neither g-irradiation nor a
chemical initiator [23], thus avoiding heat and high-
energy radiation. The polymerization mechanism is an
anionic process. Hydrophilic drugs are encapsulated with
good efficiency, such as that for ampicillin [24] and
doxorubicin [25]. The percentage of drug incorporated or
adsorbed decreases generally with the increasing amount
of drug in the polymerization medium [26]. Sparingly
water-soluble molecules such as progesterone [27], triam-
cinolone diacetate [28], can also be loaded in PACA
nanospheres but must be dissolved in a solvent such as
ether (ICH, class 3) or in a liquid surfactant before being
added to the aqueous polymerization medium. Insulin
[29], growth hormone–releasing factors (GRFs) [30], and
monoclonal antibodies [31] can also be incorporated into
PACA nanospheres.
As well, poly(dialkylmethylidene malonate) nanospheres
were prepared at pH 6 [32]. The main difference is that the
cyano group is replaced by an alkyloxycarbonyl group that
is less reactive in the presence of the hydroxide ion initiator.
Poly(diethylmethylidene malonate) nanospheres loaded
with primaquine have also been prepared at pH 7.4 [33].
The entrapment efficiency rose to 100% when the drug was
added to the polymerization medium.Interfacial polymerization
Poly(alkylcyanoacrylate) nanoparticles
One of the advantages of these polymers is their very
rapid polymerization—occurring during seconds—initiated
by ions present in the medium [34]. Cyanoacrylate
monomer and drug were dissolved in a mixture of an oil
and absolute ethanol [35]. This mixture was then slowly
extruded through a needle into a well-stirred aqueous
solution, with or without some ethanol (ICH, class 3) or
acetone (ICH, class 3) containing surfactant. Nanocapsules
are formed spontaneously by polymerization of cyanoacry-
late after contact with initiating ions present in the water.
The resulting colloidal suspension can be concentrated
by evaporation under vacuum. PECA [36], poly(isobutyl-
cyanoacrylate) [37,38], and poly(isohexylcyanoacrylate)
[39] were used in production of nanoparticles by this
process. Examples of drugs encapsulated are insulin [36,40],
calcitonin [11], octreotide [41], darodipine [42], indometh-
acin [43,44], and photoactivatable cytotoxic compounds
used in photodynamic tumor therapy like phthalocyanines in
an injectable vehicle [39]. To encapsulate highly water-
soluble drugs, another method has been proposed [45,46].
Besides the monomer, potentially toxic compounds were not
used, thus no purification procedure was necessary. The
final product was a suspension of nanocapsules in Migliol,
which is an acceptable excipient for oral administration.
Encapsulation efficiencies reached 50% and 30% for the
larger and the smaller capsules, respectively [47].
An advantage of interfacial polymerization techniques is
high-efficiency drug encapsulation (eg, insulin with 95%)
[34]. In addition, the advantage of obtaining nanocapsules
by this method is that the polymer is formed in situ,
allowing the polymer membrane to follow the contours of
the inner phase of an oil/water or water/oil emulsion [34]. In
this case, the main disadvantage is the use of organic
solvents required for the external phase. Washing of
solvents and replacement by water represents a time-
consuming and difficult procedure [3].
Fig 1. Schematic representation of the emulsification-evaporation technique.
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Polymeric nanoparticles can be also prepared by the
interfacial polycondensation of the lipophilic monomer, such
as phtaloyldichloride and the hydrophilic monomer, diethy-
lenetriamine, in the presence and absence of the surfactant
[48]. These nanoparticles were smaller than 500 nm. A
modified interfacial polycondensation method was also
developed. In this case, polyurethane polymer and poly
(ether urethane) copolymers were chosen and successfully
applied as drug carriers for a-tocopherol [49]. Polyurethane-
and poly(ether urethane)–based nanocapsules were synthe-
sized by interfacial reaction between two monomers.
Nanoparticles obtained from preformed polymers
With the exception of alkylcyanoacrylates and poly
(dialkylmethylidene malonate), most of the monomers
suitable for a micellar polymerization process in an
aqueous phase lead to slowly biodegradable or nonbiode-
gradable polymers. In addition, residual molecules in the
polymerization medium (monomer, oligomer, surfactant,
etc.) can be more or less toxic, requiring meticulous puri-
fication of the colloidal material. To avoid these limitations,
methods using preformed polymers instead of monomers
have been proposed.
Synthetic preformed polymers
Emulsification/solvent evaporationFig 2. Schematic representation of the solvent displacement technique.
**Surfactant is optional. ***In interfacial deposition method, a fifth
compound was introduced only on preparation of nanocapsules.Emulsification-solvent evaporation involves two steps.
The first step requires emulsification of the polymer solution
into an aqueous phase (see Figure 1). During the second step
polymer solvent is evaporated, inducing polymer precipita-
tion as nanospheres.
A polymer organic solution containing the dissolved
drug is dispersed into nanodroplets, using a dispersing
agent and high-energy homogenization [50], in a non-
solvent or suspension medium such as chloroform (ICH,
class 2) or ethyl acetate (ICH, class 3). The polymer
precipitates in the form of nanospheres in which the drug is
finely dispersed in the polymer matrix network. The solvent
is subsequently evaporated by increasing the temperature
under pressure or by continuous stirring [6]. The size canbe controlled by adjusting the stir rate, type and amount of
dispersing agent, viscosity of organic and aqueous phases,
and temperature [50]. Even though different types of
emulsions may be used, oil/water emulsions are of interest
because they use water as the nonsolvent; this simplifies
and thus improves process economics, because it eliminates
the need for recycling, facilitating the washing step and
minimizing agglomeration [51]. However, this method can
only be applied to liposoluble drugs, and limitations are
imposed by the scale-up of the high energy requirements in
homogenization [6]. Frequently used polymers are PLA
[52,53], PLGA [54], ethylcellulose (EC) [55], cellulose
acetate phthalate [3], poly(E-caprolactone) (PCL) [56-58],
and poly(h-hydroxybutyrate) (PHB) [59,60]. Drugs or
model drugs encapsulated were albumin [61], texanus
toxoid [62], testosterone [52], loperamide [53,63], prazin-
quantel [64], cyclosporin A [65,66], nucleic acid [67], and
indomethacin [55].
Solvent displacement and interfacial deposition
Solvent displacement and interfacial deposition are
similar methods based on spontaneous emulsification of
the organic internal phase containing the dissolved polymer
into the aqueous external phase (see Figure 2). However,
solvent displacement forms nanospheres or nanocapsules,
whereas interfacial deposition forms only nanocapsules.
Solvent displacement involves the precipitation of a
preformed polymer from an organic solution and the
diffusion of the organic solvent in the aqueous medium in
the presence or absence of a surfactant [68-71]. The polymer,
generally PLA, is dissolved in a water-miscible solvent of
intermediate polarity, leading to the precipitation of nano-
spheres. This phase is injected into a stirred aqueous solution
containing a stabilizer as a surfactant. Polymer deposition on
the interface between the water and the organic solvent,
caused by fast diffusion of the solvent, leads to the
instantaneous formation of a colloidal suspension [72]. To
facilitate the formation of colloidal polymer particles during
the first step of the procedure, phase separation is performed
with a totally miscible solvent that is also a nonsolvent of the
Fig 4. Schematic of the salting-out technique.
Fig 3. Schematic illustration of the ESD technique.
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preparation of nanocapsules when a small volume of
nontoxic oil is incorporated in the organic phase [72].
Considering the oil-based central cavities of the nano-
capsules, high loading efficiencies are generally reported
for lipophilic drugs when nanocapsules are prepared [72].
The usefulness of this simple technique [72] is limited to
water-miscible solvents, in which the diffusion rate is
enough to produce spontaneous emulsification. Then, even
though some water-miscible solvents produce a certain
instability when mixed in water, spontaneous emulsification
is not observed if the coalescence rate of the formed droplets
is sufficiently high [73]. Although, acetone/dichloromethane
(ICH, class 2) are used to dissolve and increase the
entrapment of drugs, the dichloromethane increases the
mean particle size [74] and is considered toxic. This method
is basically applicable to lipophilic drugs because of the
miscibility of the solvent with the aqueous phase [69], and it
is not an efficient means to encapsulate water-soluble drugs.
In fact, it seems difficult to choose a drug/polymer/
solvent/nonsolvent system in which particles would be
formed and the drug efficiently entrapped, because the
solvent and the nonsolvent of the polymer must be mutually
miscible. The progressive addition of the polymer solu-
tion to the nonsolvent generally leads to the formation of
nanospheres close to 200 nm in size. Nanoparticles seem to
be formed by a mechanism comparable to the bdiffusion and
standingQ process found in spontaneous emulsification. This
phenomenon has been explained by local variations of the
interfacial tension between the two immiscible liquids due
to the mutual diffusion of the third liquid. This method has
been applied to various polymeric materials such as PLA
[25], PLGA [69], PCL [75], and poly(methyl vinyl ether-co-
maleic anhydride) (PVM/MA) [76,77]. This technique was
well adapted for the incorporation of cyclosporin A, because
entrapment efficiencies as high as 98% were obtained [47].
Highly loaded nanoparticulate systems based on amphi-
philic h-cyclodextrins to facilitate the parenteral adminis-
tration of the poorly soluble antifungal drugs bifonazole and
clotrimazole were prepared according to the solvent dis-
placement method [78].
Interfacial deposition is a process used for the production
of nanocapsules; however, this is not a polymerization
technique but an emulsification/solidification technique. In
interfacial deposition, a fifth compound is introduced, of oilnature, miscible with the solvent of the polymer but
immiscible with the mixture. The polymer deposits on the
interface between the finely dispersed oil droplets and the
aqueous phase, forming nanocapsules [1]. An aqueous
solution is used as the dispersing medium. The main
difference is that polymers such as PLA are dissolved
together with the drug in a solvent mixture (eg, benzyl
benzoate, acetone, and phospholipids) [24]. This mixture is
injected slowly into a stirred aqueous medium, resulting in
the deposition of the polymer in the form of nanoparticles of
about 230 nm in size [44,68,79]. Polymer deposition occurs
at the interface between water and benzoyl nanodroplets,
forming nanocapsules with a shell-like wall [44].
Emulsification/solvent diffusion
Emulsification/solvent diffusion (ESD) was proposed in
the literature based on the use of organic solvents, and then
it was adapted to the following salting-out procedure. The
encapsulating polymer is dissolved in a partially water-
soluble solvent such as propylene carbonate (ICH not given)
and saturated with water to ensure the initial thermodynamic
equilibrium of both liquids. In fact, to produce the
precipitation of the polymer and the consequent formation
of nanoparticles, it is necessary to promote the diffusion of
the solvent of the dispersed phase by dilution with an excess
of water when the organic solvent is partly miscible with
water or with another organic solvent in the opposite case.
Subsequently, the polymer-water saturated solvent phase is
emulsified in an aqueous solution containing stabilizer,
leading to solvent diffusion to the external phase and the
formation of nanospheres or nanocapsules, according to the
oil-to-polymer ratio. Finally, the solvent is eliminated by
evaporation or filtration, according to its boiling point. The
procedure is illustrated in Figure 3.
This technique presents several advantages, such as high
encapsulation efficiencies (generally N70%), no need for
homogenization, high batch-to-batch reproducibility, ease of
scale-up, simplicity, and narrow size distribution. Disadvan-
tages are the high volumes of water to be eliminated from
the suspension and the leakage of water-soluble drug into the
saturated-aqueous external phase during emulsification, reduc-
ing encapsulation efficiency. As with some of the other tech-
niques, this one is efficient in encapsulating lipophilic drugs
Fig 5. Schematic representation of the emulsification–internal gelation technique using alginate.
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the ESD technique, including mesotetra(hydroxyphenyl)
porphyrin-loaded PLGA (p-THPP) nanoparticles [80,81],
doxorubicin-loaded PLGA nanoparticles [82], plasmid
DNA-loaded PLA nanoparticles [83], coumarin-loaded
PLA nanoparticles [84], indocyanine [85], cyclosporin
(Cy-A)-loaded gelatin and cyclosporin (Cy-A)-loaded sodium
glycolate nanoparticles [86].
Salting out with synthetic polymers
Salting-out is based on the separation of a water-
miscible solvent from aqueous solution via a salting-out
effect. The salting-out procedure can be considered as a
modification of the emulsification/solvent diffusion. Poly-
mer and drug are initially dissolved in a solvent such as
acetone, which is subsequently emulsified into an aqueous
gel containing the salting-out agent (electrolytes, such as
magnesium chloride, calcium chloride, and magnesium
acetate, or non-electrolytes such as sucrose) and a colloidal
stabilizer such as polyvinylpyrrolidone or hydroxyethylcel-
lulose. This oil/water emulsion is diluted with a sufficient
volume of water or aqueous solution to enhance the
diffusion of acetone into the aqueous phase, thus inducing
the formation of nanospheres. The selection of the salting-
out agent is important, because it can play an important role
in the encapsulation efficiency of the drug. Both the solvent
and the salting-out agent are then eliminated by cross-flow
filtration [72].
This technique used in the preparation of PLA, poly-
(methacrylic) acid, and EC nanospheres leads to high
efficiency and is easily scaled up [72]. The main advantage
of salting out is that it minimizes stress to protein
encapsulants [7]. Salting out does not require an increase
of temperature and, therefore, may be useful when heat-
sensitive substances have to be processed [87]. The
greatest disadvantages are exclusive application to lipo-
philic drugs and the extensive nanoparticle washing steps
[1]. The preparative steps of this procedure are described
in Figure 4.Production of nanoparticles from natural
macromolecules
Albumin nanoparticles produced in an external-oily emulsion
Two main methods are used in the preparation of albumin
microspheres, characterized by the method of stabilization;
thermal treatment at elevated temperatures (958–1708C) or
chemical treatment in vegetable oil, iso-octane emulsions, or
aqueous medium. Other techniques involve slight modifica-
tion of either of the two methods [88]. In this case albumin
nanospheres were formed by homogenizing the oil phase
containing the albumin droplets and thermally stabilized by
heating at 1758 to 1808C for 10 minutes [88]. This mixture
was cooled and diluted with ethyl ether to reduce the viscosity
of the oil phase to permit separation by centrifugation.
Heat treatment of albumin is applicable only to drug
molecules that are not heat sensitive. For this reason,
nanoparticles were produced emulsifying serum albumin
aqueous solution in cottonseed oil at 258C [89], then
denaturing the albumin by resuspending the particles in ether
containing the cross-linking agents 2,3-butadiene or formal-
dehyde. The particles were stirred, isolated by centrifugation,
and dried by lyophilization. Particles released the drug
doxorubicin much faster than particles formed by heat
treatment [89], but the purification step remains the main
problem with the elimination of the cottonseed oil [3]. A
technique was proposed based on the desolvation of natural
macromolecules, which simplifies the purification step [90].
As a modification of this method [91], an aqueous
solution of albumin was emulsified in chloroform contain-
ing hydroxypropylcellulose and EC as stabilizers. The
emulsified macromolecule is subsequently cross-linked with
glutaraldehyde and washed. Because of the need for
chlorinated solvents, this technique does not offer much
advantage over the other techniques [90].
Gelatin nanoparticles produced in an external-oily emulsion
Emulsified gelatin solution droplets were hardened by
cooling the emulsion below the gelation point in an ice bath,
Fig 6. Schematic representation of chitosan nanoparticles preparation by the emulsification technique.
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droplets were filtered, washed, and cross-linked with
formaldehyde [92]. The particle size ranged between 100
and 600 nm with a mean of 280 nm [23]. This technique is
applicable to heat-sensitive drugs; however, a number of
drugs can be covalently bound to the gelatin by formalde-
hyde treatment, which constitutes a disadvantage [23].
Additionally, cross-linking increases significantly the size
of the particles. Furthermore, a significant disadvantage of
the cross-linking agent relates to its toxicity, and this point
must be carefully considered. In this context, it would be of
interest to study carefully the influence of different
formulation and process parameters in this process accord-
ing to the application.
Another interesting system for drug delivery systems
could be nanoparticulate carriers from bioacceptable macro-
molecules. For this reason, vegetable protein fractions termed
gliadins have been chosen from wheat gluten, to efficiently
encapsulate lipophilic substances such as a-tocopherol [93].
Gliadins possess the ability to interact with epidermal keratin
as a result of their richness in praline; this property leads to a
desired controlled release of drug.
Alginate nanoparticles
Sodium alginate is a water-soluble polymer that gels in
the presence of multivalent cations such as calcium [94].
Alginate particles are usually produced by dropwise
extrusion of sodium alginate solution into calcium chloride
solution. Alginate particle size depends on the size of the
initial extruded droplet. The smallest particles produced had
a minimum size of 1 to 5 Am, obtained by air atomization
[95]. The preparation of alginate nanoparticles was first
achieved in a diluted aqueous sodium alginate solution in
which gelation was induced by the addition of a low
concentration of calcium. This leads to the formation of
invisible clusters of calcium alginate gels. In an additional
advance, alginate particles have been produced by using a
modified emulsification/internal gelation method [96] as
illustrated in Figure 5. The preparation of alginate nano-
particles via this method does not require specialized
equipment and can be performed at ambient temperature.
The main difficulty of this method is the nanoparticlewashing step to eliminate the residual oil droplets, but new
strategies have been devised.
Chitosan nanoparticles
Chitosan nanoparticles have been developed to encapsu-
lated proteins such as bovine serum albumin, tetanus and
diphtheria toxoid [6], vaccines [97], anticancer agents [98],
insulin [99], and nucleic acids [100,101]. Chitosan consid-
erably enhanced the absorption of peptides such as insulin
and calcitonin across the nasal epithelium [102].
The methods proposed to prepare chitosan nanoparticles
are based on the spontaneous formation of complexes
between chitosan and polyanions [103] or the gelation of a
chitosan solution dispersed in an oil emulsion [104]. Various
methods for producing chitosan nanoparticles are described
in the literature [105,106].
Chitosan nanoparticles obtained by formation of a spon-
taneous complex between chitosan and polyanions such as
tripolyphosphate [103] have small diameters (200–500 nm)
and show a quasi spherical shape under transmission electron
microscopy. Chitosan nanoparticles produced by a promot-
ing gelation in an emulsification-based method as illustrated
in Figure 6, results in a diameter of 400 nm. Compared with
the previously described method, this technique has a major
disadvantage of involving organic solvents during the
isolation of the particles; these are difficult to remove and
may cause toxicity [107].
Agarose nanoparticles
Agarose nanoparticles were developed for the adminis-
tration of therapeutic proteins and peptides [108]. Agarose
aqueous solution forms thermally reversible hydrogels while
being cooled below the gelling temperature (318–368C).
Thermal gelation results from the formation of helicoidal
structures responsible for a three-dimensional network in
which large amounts of water can be entrapped. The
hydrogel, being hydrophilic, inert, and biocompatible, forms
a suitable matrix for proteins and peptides that can be
entrapped in the gel during formation [107].
Agarose nanoparticles were produced using an emul-
sion-based technology as illustrated in Figure 7. This
methodology requires the preparation of an agarose
Fig 7. Schematic illustration of agarose nanoparticles preparation by the emulsification technique.
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proteins to be encapsulated are initially added to the
agarose solution. The small size of the dispersed aqueous
nanodroplets is achieved by homogenization. Gelation of
agarose is then induced by diluting the emulsion with
cold corn oil under agitation at 58C. The liquid nano-
droplets then gel to protein-containing agarose hydrogel
nanoparticles.Nanoparticles produced by desolvation
of macromolecules
Another technology applicable to a wide range of
polymers is based on desolvation by charge and pH
changes, or by addition of a desolvating agent (ethanol
or concentrated inorganic salt solutions). The main advan-
tage is that this process does not require an increase in
temperature and, therefore, may be useful when heat-
sensitive drugs are used [110].
Nanoparticles were prepared using the process of
reversible swelling of macromolecules [90,111] using gelatin
[111], human serum albumin [111], bovine serum albumin
[112], and casein [111] as the macromolecular materials.
This process offers the advantage of producing nano-
particles directly in aqueous suspension, but the use of
potentially toxic compounds such as glutaraldehyde and
desolvating agents requires subsequent purification [1].
Variations in nanoparticle production by the desolvation
process were described [113], but unfortunately the yield is
comparatively low. In the case of gelatin, different methods
such as the two-step desolvation method [114,115] have
been applied to produce nanoparticles. Recent reports
outline the important use of gelatin as drug delivery systems
for DNA [116] and cytostatics [117].
New techniques based on supercritical or compressed fluids
Some of the techniques described above are complex,
and the products may often be characterized by high
residual solvent content, low drug loading, drug degradation
or denaturation, ineffective drug release, or unsuitable
physical and morphological properties [118]. Techniques
based on supercritical or compressed fluid can be an
interesting tool for preparation of nanoparticulate and
microparticulate products [119]. In this technique, the drugand the polymer are solubilized in a supercritical fluid, and
the solution is expanded through a nozzle. The supercritical
fluid is evaporated in the spraying process, and the solute
particles eventually precipitate. This technique is clean,
because the precipitated solute is free of solvent. It also
provides advantages such as suitable technological and
biopharmaceutical properties and high quality. It has been
demonstrated for numerous applications involving protein
drug delivery systems. Protein drugs such as insulin were
encapsulated in poly(ethylene glycol)/poly(l-lactide) (PEG/
PLA) nanoparticles by this technique [130]. However, this
new process requires a high initial capital investment for
equipment, and elevated operating pressures requiring high-
pressure equipment. In addition, compressed supercritical
fluids require elaborate recycling measures to reduce energy
costs. Finally, it is very difficult to dissolve strong polar
substances in supercritical CO2. In fact, supercritical CO2
has solvating properties characteristic of both fluorocarbons
and hydrocarbons. However, the use of cosolvents and/or
surfactants to form microemulsions makes it possible to
dissolve polar and ionic species.
Stability upon storage of the nanoparticles
Nanoparticles are intended to be administered as
pharmaceutical dosage forms in humans. Among other
requirements, they must be free of impurities. The necessity
for and degree of purification are dependent on the final
purpose of the formulation developed. The most commonly
reported procedures are gel filtration, ultracentrifugation,
dialysis, and, recently, cross-flow filtration. Another re-
quirement relates to the sterilization of the formulation. The
choice of the sterilizing treatment depends on the physical
susceptibility of the system. Finally, nanoparticles should be
easily stored and administered. Nanoparticles constitute a
relatively stable physical system because of their colloidal
nature. Many variables can affect the stability of nano-
particles. Generally, a colloidal suspension is stable and
does not tend to separate as a result of slow deposition due
to the mixing tendencies of diffusion and convection.
However, some agglomeration can occur. To prevent a
complete precipitation, it is necessary to incorporate some
additives. Chemical integrity of drug is also a fundamental
aspect of the overall stability evaluation of the nano-
particles. Some parameters are crucial for the stability, such
Table 2
Polymeric nanoparticles: general advantages and drawbacks of the preparation methods
Method Simplicity
of procedure
Need
for purification
Facility
scaling-up
EE
(%)
Safety
of compounds
Polymerization of monomers
Emulsion polymerization
Organic Low High NR Low Low
Aqueous High High High High Medium
Interfacial polymerization Low High Medium High Low
Preformed polymers
Synthetic
Emulsification/solvent evaporation High Low Low Medium Medium
Solvent displacement and
interfacial deposition
High NR NR High Medium
Salting out High High High High Low
Emulsion/solvent diffusion Medium Medium High High Medium
Natural
Albumin NR High NR Medium Low
Gelatin NR High NR Medium Low
Polysaccharides
Alginate High Medium High High High
Chitosan High Medium High High High
Agarose Medium High NR NR High
Desolvation NR High NR Low Low
EE, encapsulation efficiency; NR, no reference available.
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when the drug is water soluble, the surrounding pH when
drug degradation is pH dependent, and light exposure when
the drug is light sensitive. Stability studies are thus
important and can be performed according to the drug and
to the polymer properties.
There are some methods to increase the stability of
the nanoparticles. Lyophilization (freeze-drying) seems to
be a highly stabilizing process. It is generally applied to
enhance the physicochemical stability of the nanoparticles
to achieve a pharmaceutically acceptable product, especial-
ly in cases in which the storage conditions are unfavorable.
This technique involves the freezing of the suspension
and subsequent elimination of its water content by
sublimation under reduced pressure. After complete desic-
cation, nanoparticles are obtained in the form of a dry
powder that is easy to handle and store. In most cases the
freeze-dried particles are readily dispersible in aqueous
solutions. In some systems the ease of redispersion
depended on the manufacturing process. Ultrasonication
was applied by some authors to ensure complete redis-
persion of nanoparticles.
Freezing is the most aggressive step of the freeze-drying
operation for colloidal operations. It is thus important to
improve the nanoparticle resistance by addition of a
cryoprotectant to avoid alteration of the suspension [120].
Sometimes cryoprotectants like glucose, trealose, mannitol,
and sorbitol were added to ensure redispersibilty or to allow
vitrification of the suspension during the cooling and to avoid
crystallization of the liquid suspension. It is also important to
be aware of the presence of pharmaceutical excipients,
usually used for purposes of isotonicity (eg, glucose) or
stabilization (eg, dextran and surfactants). Such excipients
are indeed cryoprotectants that facilitate the aqueous recon-
stitution of the freeze-dried product.Finally, nanoparticles can be stored in sealed vials at
room temperature, or in a laboratory desiccator, or even in
the refrigerator, especially for temperature-sensitive drugs.Summary and conclusions
The most important methods for the preparation of
nanoparticulate drug carriers, together with their advantages
and disadvantages, are summarized in Table 2.
The evolution of nanoparticle preparation methods has
been marked by three aspects: need for less toxic reagents,
simplification of the procedure to allow economic scale-up,
and optimization to improve yield and entrapment efficien-
cy. Efficient drug entrapment and transition to large scale
are of utmost importance to industrial applicability.
There are now numerous preparation methods available
for producing nanoparticles, and important technological
advances have been achieved. Simple, safe, and reproducible
techniques are now available to prepare drug-loaded nano-
spheres and nanocapsules. Depending on the physicochem-
ical characteristics of a drug, it is now possible to choose the
best method of preparation and the best polymer to achieve an
efficient entrapment of the drug. The chosen method should
minimize loss of the drug or its pharmacological activity. In
this respect, the development of a technique that allows the
incorporation of biomolecules without affecting their activity
constitutes a fundamental goal for nanotechnology.
Nevertheless, there are several problems that remain to be
solved. The process is not suitable to all drugs. In addition,
the postpreparative steps, such as purification and preserva-
tion, particularly important for nanocapsules, and residual
solvent analysis must be extensively investigated. Other
difficulties remain, such as the formation of an incomplete or
discontinuous film, inadequate stability of certain active
components, nonreproducible or predictable release charac-
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economically unfeasible.
Despite these technological challenges, nanoparticles
have shown great promise for the development of drug
administration.References
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